Real-World Experience with Anti-CGRP Migraine Antibodies in Large US Health Plan
Large real-world study reports treatment persistence, patient satisfaction, and outcomes with anti-CGRP monoclonal antibodies for migraine prevention in a US healthcare network.
Quick Facts
What This Study Found
Real-world data from a large US healthcare plan demonstrates treatment persistence patterns and patient satisfaction with self-injectable anti-CGRP monoclonal antibodies for migraine prevention.
Key Numbers
How They Did This
Observational real-world study (Migraine Signature Study) of patients prescribed ≥1 self-injectable anti-CGRP mAb in a large US healthcare network, measuring persistence and patient-reported outcomes.
Why This Research Matters
Clinical trial results don't always match real-world experience. This study provides the data patients and doctors need to make informed migraine treatment decisions.
The Bigger Picture
Real-world evidence is essential for understanding the true value of migraine preventive therapies as they mature beyond initial clinical trial enthusiasm.
What This Study Doesn't Tell Us
Observational design — no control group. Self-reported outcomes may have recall bias. Single healthcare plan may not represent all patient populations.
Questions This Raises
- ?What factors predict who will persist on anti-CGRP therapy long-term?
- ?How do satisfaction levels compare across different anti-CGRP antibodies?
Trust & Context
- Key Stat:
- Real-world persistence data Large US health plan tracking anti-CGRP antibody use patterns and patient satisfaction
- Evidence Grade:
- Large observational real-world study — provides valuable practical data but lacks the rigor of controlled trials.
- Study Age:
- Published in 2026; reflects mature anti-CGRP prescribing patterns.
- Original Title:
- Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.
- Published In:
- Neurology and therapy, 15(1), 401-420 (2026)
- Authors:
- Buse, Dawn C(5), Lipton, Richard B(9), Urman, Robert(2), Vaidya, Shruti J, Robinson, Sarah C, Jacobson, Alice S, Scott, Alexandra B, Bensink, Mark E, Pressman, Alice R
- Database ID:
- RPEP-14914
Evidence Hierarchy
Frequently Asked Questions
Do anti-CGRP migraine drugs work in real life?
This large real-world study shows that anti-CGRP antibodies provide meaningful migraine prevention outside of clinical trials, though individual responses vary and some patients discontinue treatment.
How long should I try anti-CGRP therapy?
Guidelines typically recommend at least 3 months to assess response. This study provides real-world data on how long patients actually stay on these medications and their satisfaction levels.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-14914APA
Buse, Dawn C; Lipton, Richard B; Urman, Robert; Vaidya, Shruti J; Robinson, Sarah C; Jacobson, Alice S; Scott, Alexandra B; Bensink, Mark E; Pressman, Alice R. (2026). Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.. Neurology and therapy, 15(1), 401-420. https://doi.org/10.1007/s40120-025-00872-1
MLA
Buse, Dawn C, et al. "Real-World Experience with Anti-CGRP Pathway Monoclonal Antibodies in a Large United States Healthcare Plan: Results of the Migraine Signature Study.." Neurology and therapy, 2026. https://doi.org/10.1007/s40120-025-00872-1
RethinkPeptides
RethinkPeptides Research Database. "Real-World Experience with Anti-CGRP Pathway Monoclonal Anti..." RPEP-14914. Retrieved from https://rethinkpeptides.com/research/buse-2026-realworld-experience-with-anticgrp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.